Overview
Qualitative or quantitative defects of Torsin-1A-interacting protein 1 is an extremely rare genetic condition caused by changes in the TOR1AIP1 gene. This gene provides instructions for making a protein called LAP1 (Lamina-associated polypeptide 1), which plays an important role in keeping the nucleus — the control center of each cell — working properly. LAP1 also helps regulate another protein called Torsin-1A, which is involved in maintaining the structure of cells and helping muscles function normally. When the TOR1AIP1 gene is not working correctly, either because it makes too little protein or a faulty version of it, cells throughout the body — especially muscle cells and nerve cells — cannot function as they should. This leads to a condition that mainly affects the muscles and nervous system. People with this condition may experience progressive muscle weakness, problems with heart muscle function (cardiomyopathy), and neurological difficulties. The severity can vary from person to person. Currently, there is no cure for this condition. Treatment focuses on managing symptoms, supporting heart and muscle function, and improving quality of life. Because this disease is so rare, it is still being studied, and the full range of symptoms and best treatment approaches are not yet completely understood. Early diagnosis through genetic testing is important so that appropriate monitoring and care can begin as soon as possible.
Key symptoms:
Progressive muscle weaknessHeart muscle disease (cardiomyopathy)Muscle wasting over timeDifficulty walking or movingAbnormal muscle tone (too floppy or too stiff)Fatigue and low energyBreathing difficulties due to weak respiratory musclesIntellectual disability or developmental delays (in some cases)Abnormal heart rhythm (arrhythmia)Joint stiffness or contractures
Autosomal recessive
Passed on when both parents carry the same gene change; often skips generations
Variable
Can begin at different ages, from infancy through adulthood
Treatments
No FDA-approved treatments are currently listed for Qualitative or quantitative defects of Torsin-1A-interacting protein 1.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Qualitative or quantitative defects of Torsin-1A-interacting protein 1 at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Qualitative or quantitative defects of Torsin-1A-interacting protein 1.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Qualitative or quantitative defects of Torsin-1A-interacting protein 1.
Community
No community posts yet. Be the first to share your experience with Qualitative or quantitative defects of Torsin-1A-interacting protein 1.
Start the conversation →Latest news about Qualitative or quantitative defects of Torsin-1A-interacting protein 1
No recent news articles for Qualitative or quantitative defects of Torsin-1A-interacting protein 1.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Questions for your doctor
Bring these to your next appointment
- Q1.What specific changes were found in my TOR1AIP1 gene, and what do they mean for my health?,How often should my heart be monitored, and what tests will be used?,Are there any physical activities I should avoid to protect my heart and muscles?,Should other family members be tested for this condition?,Are there any clinical trials or research studies I could participate in?,What signs should prompt me to go to the emergency room immediately?,What therapies — such as physical or occupational therapy — would help me maintain my strength and independence?
Common questions about Qualitative or quantitative defects of Torsin-1A-interacting protein 1
What is Qualitative or quantitative defects of Torsin-1A-interacting protein 1?
Qualitative or quantitative defects of Torsin-1A-interacting protein 1 is an extremely rare genetic condition caused by changes in the TOR1AIP1 gene. This gene provides instructions for making a protein called LAP1 (Lamina-associated polypeptide 1), which plays an important role in keeping the nucleus — the control center of each cell — working properly. LAP1 also helps regulate another protein called Torsin-1A, which is involved in maintaining the structure of cells and helping muscles function normally. When the TOR1AIP1 gene is not working correctly, either because it makes too little prot
How is Qualitative or quantitative defects of Torsin-1A-interacting protein 1 inherited?
Qualitative or quantitative defects of Torsin-1A-interacting protein 1 follows a autosomal recessive inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.